Covaxin Phase 2, 3 Clinical Trials for 2-18 Age Group Get Green Signal from DCGI

New Delhi: The Drug Controller General of India (DGCI) on Thursday gave permission to Bharat Biotech to conduct clinical trials of its Covid-19 vaccines Covaxin on children belonging to the age group of 2 to 18 years.

Bharat Biotech will conduct the trials on 525 healthy volunteers, including AIIMS, Delhi, AIIMS, Patna and Meditrina Institute of Medical Sciences, Nagpur, the Hyderabad-based firm said. After critical examination, DCGI has accepted the recommendation of the Subject Expert Commitee (SEC) on Covid-19 and accorded permission to conduct the phase 2-3 clinical trial of Covaxin on the age group 2-18 years.

Covaxin, indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), is being used in adults in India’s ongoing COVID-19 vaccination drive.